ECSP19044926A - IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING - Google Patents

IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING

Info

Publication number
ECSP19044926A
ECSP19044926A ECSENADI201944926A ECDI201944926A ECSP19044926A EC SP19044926 A ECSP19044926 A EC SP19044926A EC SENADI201944926 A ECSENADI201944926 A EC SENADI201944926A EC DI201944926 A ECDI201944926 A EC DI201944926A EC SP19044926 A ECSP19044926 A EC SP19044926A
Authority
EC
Ecuador
Prior art keywords
lansoprazole
symeticone
preparing
improved composition
microgranules
Prior art date
Application number
ECSENADI201944926A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61196457&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP19044926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of ECSP19044926A publication Critical patent/ECSP19044926A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de administración oral, que comprende la combinación a dosis fija de Simeticona en microgránulos de alta concentración y Lansoprazol o su enantiómero (Dexlansoprazol) en microgránulos de liberación entérica y el proceso para obtener los microgránulos de alta concentración de SimeticonaThe present invention refers to a pharmaceutical composition for oral administration, which comprises the fixed dose combination of Simethicone in high concentration microgranules and Lansoprazole or its enantiomer (Dexlansoprazole) in enteric release microgranules and the process to obtain the high concentration microgranules by Simethicone

ECSENADI201944926A 2016-08-17 2019-06-25 IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING ECSP19044926A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016010682A MX384961B (en) 2016-08-17 2016-08-17 IMPROVED COMPOSITION OF TENELIGLIPTIN AND METFORMIN AND PROCESS FOR PREPARING SAME.

Publications (1)

Publication Number Publication Date
ECSP19044926A true ECSP19044926A (en) 2019-07-31

Family

ID=61196457

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI201910066A ECSP19010066A (en) 2016-08-17 2019-02-12 IMPROVED COMPOSITION OF TENELIGLIPTIN AND METFORMIN AND PROCESS TO PREPARE IT
ECSENADI201944926A ECSP19044926A (en) 2016-08-17 2019-06-25 IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ECSENADI201910066A ECSP19010066A (en) 2016-08-17 2019-02-12 IMPROVED COMPOSITION OF TENELIGLIPTIN AND METFORMIN AND PROCESS TO PREPARE IT

Country Status (8)

Country Link
AR (1) AR109253A1 (en)
CL (1) CL2019000273A1 (en)
CO (1) CO2019001110A2 (en)
DO (1) DOP2019000035A (en)
EC (2) ECSP19010066A (en)
MX (1) MX384961B (en)
PE (1) PE20190402A1 (en)
WO (1) WO2018033808A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions

Also Published As

Publication number Publication date
PE20190402A1 (en) 2019-03-13
BR112019002909A2 (en) 2019-05-21
MX384961B (en) 2025-03-14
AR109253A1 (en) 2018-11-14
MX2016010682A (en) 2018-02-16
DOP2019000035A (en) 2019-06-30
CO2019001110A2 (en) 2019-04-12
WO2018033808A1 (en) 2018-02-22
ECSP19010066A (en) 2019-11-30
CL2019000273A1 (en) 2019-06-28

Similar Documents

Publication Publication Date Title
ECSP22023220A (en) MONO OR DISUBSTITUTED INDOL DERIVATIVES AS INHIBITORS OF DENGUE VIRAL REPLICATION
JOP20180025A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
AR128459A2 (en) ROLLER-COMPRESSED SOLID PHARMACEUTICAL COMPOSITION AND THE PROCESS FOR ITS MANUFACTURE
CO2018003369A2 (en) Indole mono- or disubstituted derivatives as inhibitors of dengue viral replication
UY36339A (en) MONKEY OR DISABLED INDOLES AS INHIBITORS OF THE DENGUE VIRUS REPLICATION
BR112017008993A2 (en) Methods and Compositions Specifically for the Treatment of Attention Deficit Disorder
UY36518A (en) DERIVATIVES OF INDOL MONO OR DISABLED AS INHIBITORS OF THE REPLICATION OF DENGUE VIRUSES
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
CL2016002560A1 (en) Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure
CL2017001483A1 (en) Fixed ratio formulation of insulin glargine / lixisenatide
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
MX2017009849A (en) COMPOSITIONS OF MONOMETILFUMARATE PROPHARMACO.
UY36124A (en) CARBOXAMIDE DERIVATIVES
CY1121986T1 (en) SOLID PHARMACEUTICAL COMPOSITION OF CYTISIN AND PROCESS FOR PREPARATION THEREOF
MX385518B (en) FORMULATION HAVING ENHANCED pH-DEPENDENT DRUG RELEASE CHARACTERISTICS, CONTAINING ESOMEPRAZOLE OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
BR112017026272A2 (en) compound, pharmaceutical composition, method for treating a muscarinic m1 receptor-related disorder and use of the compound
CL2020000601A1 (en) Pharmaceutical composition.
MX2016014740A (en) A METHOD FOR THE TREATMENT OF MOVEMENT DISORDERS WITH BEFIRADOL.
AR108233A1 (en) ORIC PHARMACEUTICAL COMPOSITIONS OF NICOTINAMIDE
ECSP19044926A (en) IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING
DOP2019000145A (en) IMPROVED COMPOSITION OF LANSOPRAZOLE AND SYMETICONE AND PROCESS FOR PREPARING
MX2015007749A (en) Pharmaceutical composition of amanthadine hydrochloride-loratadin e-paracetamol in a capsule for treating colds amongst other allopathy.
DOP2019000190A (en) QUICK RELEASE COMPOSITION OF CINITAPRIDA AND SYMETICONE AND PROCESS TO PREPARE IT.